Immuron FY23 Sales increase 136% on FY22 Sales
05 juil. 2023 06h00 HE
|
Immuron Limited
Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales)USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales)Global FY23 sales of A$1.80 M (136% increase on FY22 sales) ...
Immuron Chairman Transition
30 juin 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the...
Immuron Business Update: Letter to Shareholders
22 juin 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submissionRecruitment and screening update for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Initiates Recruitment of Travelan® Clinical Study
30 mai 2023 06h00 HE
|
Immuron Limited
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM)...
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
08 mai 2023 06h00 HE
|
Immuron Limited
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily...
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
02 mai 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Q3 FY23 Business Update Presentation
19 avr. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Q3 FY23 Business Update Webinar Notification
11 avr. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...
Immuron Q3 Sales reach 150% of 1H Sales
06 avr. 2023 06h00 HE
|
Immuron Limited
Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales)North American Q3 FY23 Travelan® sales of A$298 k (100% of 1H sales)Global Q3 YTD FY23 sales of A$1.46 M represent an increase of...
Immuron CEO, Steven Lydeamore to host an investor webinar
15 févr. 2023 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two...